HIV-1 new infection detection reagent|Scientific research reagent|Beijing Key-Bio Biotech Co., Ltd.

HIV-1 new infection detection reagent

Product overview

This reagent employs the restriction antigen affinity enzyme-linked immunosorbent assay (LAg-AvidityEIA). By detecting the affinity level of anti-HIV-1 restriction antigen lgG antibodies in serum/plasma, it distinguishes new HIV-1 infections from previous infections at the population level and is used to calculate the new infection rate in specific populations. Compared with the traditional BED method, the LAg-Avidity method is less affected by the immune status of the infected person and the virus subtype, has higher specificity, is simple to operate, and is applicable to multiple subtypes of HIV-1. At present, worldwide, the detection of new HIV-1 infections has gradually replaced the BED method with the LAg-Avidity method.

Detailed introduction

【Monitoring Significance】

The monitoring of new HIV infection rates provides a scientific basis for the early detection of high-risk groups for HIV transmission, timely grasp of the epidemic trend of the disease, rational allocation of limited prevention and control resources, and evaluation of the effectiveness of intervention measures.

【Application Scenarios】

The scientific basis for the allocation of AIDS prevention and control resources

Estimation of new infection rates through sentinel surveillance and cross-sectional surveys

Epidemiological assessment of the effectiveness of intervention measures

【Basic Product Information】

Product Name: HIV-1 new infection detection reagent

Detection principle: Restriction antigen affinity method

Packaging specification: 192 servings per box (96T×2

Sample type: Serum/plasma

Average positive conversion time: approximately 130 days (ω)

Storage conditions: Refrigerate 2-8°C/ freeze -20°C

Applicable instruments: Microplate reader 450/620-630nm